Breakeven Is Near for Heron Therapeutics, Inc. (NASDAQ:HRTX) [Yahoo! Finance]
Heron Therapeutics, Inc. (HRTX)
Last heron therapeutics, inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
herontherapeutics.gcs-web.com/investor-home
Company Research
Source: Yahoo! Finance
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The US$260m market-cap company's loss lessened since it announced a US$14m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$14m, as it approaches breakeven. As path to profitability is the topic on Heron Therapeutics' investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Heron Therapeutics is bordering on breakeven, according to the 4 American Biotechs analysts. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$3.7m in 2026. The company is therefore projected to breakeven around a year from now or le
Show less
Read more
Impact Snapshot
Event Time:
HRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HRTX alerts
High impacting Heron Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HRTX
News
- Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M [Yahoo! Finance]Yahoo! Finance
- Heron Therapeutics (NASDAQ:HRTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 GrowthGlobeNewswire
- Heron Therapeutics, Inc. (NASDAQ:HRTX) is favoured by institutional owners who hold 57% of the company [Yahoo! Finance]Yahoo! Finance
- Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)GlobeNewswire
HRTX
Earnings
- 11/4/25 - Miss
HRTX
Analyst Actions
- 1/9/26 - HC Wainwright
HRTX
Sec Filings
- 2/3/26 - Form 4
- 2/3/26 - Form 4
- 2/3/26 - Form 4
- HRTX's page on the SEC website